Therapeutic effect improvement by new boron neutron capture therapy with amino acid - BSH

硼中子俘获疗法（BNCT）是基于核俘获和裂变反应，当非放射性硼-10用低能热中子照射时发生核俘获和裂变反应，以在一个细胞水平内产生α粒子。与正常细胞相比，肿瘤细胞中的L-氨基酸转运系统增强。我们设计、合成并测试了BNCT的含硼非天然氨基酸药物ACBC-BSH。ACBC-BSH组与BPA组疗效相当。其原因是我们认为ACBC-BSH的细胞外蓄积表明看似高的肿瘤硼浓度并不代表真实的肿瘤细胞摄取。我们没有竞争的疗效，ACBC-BSH在BPA和接受有意义的生存时间。认为细胞水平药物分布的差异是其原因。本研究提示ACBC-BSH有可能成为治疗该病的增效药物。

Boron neutron capture therapy (BNCT) is based on the nuclear capture and fission reactions that occur when non-radioactive Boron-10 is irradiated with low energy thermal neutrons to produce alpha- particles inside one cell level. The L-amino acid transport system in tumor cells is enhanced compared with normal cells. We designed, synthesized and tested boron carrying unnatural amino-acid, ACBC-BSH, as boron drug for BNCT. Curative effect of ACBC-BSH groups was approximately equal to BPA. The reason is that we think that extracellular accumulations of ACBC-BSH indicating that the seemingly high tumor boron concentrations did not represent the true tumor cellular uptake. And we did not compete for the curative effect by using ACBC-BSH together in BPA and accepted meaningful duration of survival time. Difference in drug distribution at the cell level was regarded as the cause. This study suggested the possibility that ACBC-BSH became the drug to add curative effect to.